Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting
STOCKHOLM, May 12, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that new clinical and preclinical data have been accepted by the European Hematology Association, EHA, and been published online. The clinical data presentation contains interim results from the phase 2 BRIDGE study supporting the use of melflufen in relapsed refractory multiple myeloma patients with moderately impaired renal function. Two preclinical data presentations show the future potential of melflufen in treatments of other hematological diseases outside multiple myeloma. In addition, the last preclinical data presentation provides an increased understanding of melflufen s mode of action.
Oncopeptides completes patient enrollment in phase 2 PORT study
News provided by
Share this article
Share this article
STOCKHOLM, May 5, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has completed patient enrollment in the phase 2 PORT study. The PORT study is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen (INN melphalan flufenamide) in combination with dexamethasone in relapsed refractory multiple myeloma. Oncopeptides expects topline data in Q3 2021. I am very pleased that we have enrolled the final patient in the PORT study, said Klaas Bakker, MD, PhD and Chief Medical Officer at Oncopeptides. The data could potentially provide a pathway for us to work with the U.S. Food and Drug Administration to
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Apollo Hybrid Value to Invest in Standard Industries Holdings’ Acquisition of Grace
Apollo Global Management, Inc.April 30, 2021 GMT
NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo” or the “Firm”) announced that certain funds managed by its affiliates have committed to invest $600 million as part of an agreement in which Standard Industries Holdings Inc. will acquire W.R. Grace & Co. (“Grace”) (NYSE: GRA), a leading global specialty chemicals company, in an all-cash transaction valued at approximately $7.0 billion.
/PRNewswire/ Oncopeptides AB (Nasdaq Stockholm: ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the directed.